Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine

Table 1

Demographics and clinical characteristics of MS patients. RR, relapsing-remitting; SP, secondary progressive; EDSS, Expanded Disability Status State; INF, Interferon; No, patients without Amantadine; Th., patients treated with Amantadine; Ham-A, Hamilton anxiety; Ham-D, Hamilton depression; FSS, Fatigue Severity Scale; FIS, Fatigue Impact Scale; ESS, Epworth Sleepiness Scale.

Sex, age	SM type	EDSS	Therapy	Dur.	Ham-A		Ham-D		Beck		FSS		FIS		ESS
					No	Th	No	Th	No	Th	No	Th	No	Th	No	Th
F, 29	RR	1	No	—	1	1	2	2	3	3	3.8	3.3	84	81	8	9
F, 43	RR	1.5	INF-1a (44 × 3)	7	0	0	1	1	1	1	6.4	6.2	153	144	19	14
F, 46	SP	3	No	—	1	1	1	1	3	2	3.6	3	19	11	5	5
F, 37	RR	1	No	—	0	0	1	0	2	0	6.2	4.3	60	34	15	10
F, 64	SP	5.5	INFβ-1b	15	0	0	0	0	3	1	6.4	6.7	89	76	10	15
F, 28	RR	1.5	INF-1a (44 × 3)	6	0	0	1	1	4	2	5.8	4.2	98	72	6	3
F, 22	RR	1	INF-1a (22 × 3)	24	3	3	2	2	9	8	7	7	96	102	3	3
F, 33	RR	2.5	No	—	1	2	3	3	6	6	5.8	4.2	98	78	9	9
F, 28	RR	2	No	—	3	3	1	1	8	7	6.2	5	130	90	11	9
F, 29	RR	2	INF-1a (44 × 3)	8	4	4	3	3	4	5	5.8	4	110	85	4	2
Mean		2.1			1.3	1.4	1.5	1.4	4.3	3.5	5.7	4.8	93.7	77.3	9.0	7.9
SD		1.4			1.5	1.5	1.0	1.1	2.6	2.8	1.1	1.4	36.5	35.9	5.0	4.6

, Wilcoxon matched-pairs signed rank test.